Multinuclear-selective MR Spectroscopy Imaging Platform for Single-scan Lipid/water Suppression and Metabolite Mapping

This approach stands apart by delivering comprehensive lipid and water suppression in one acquisition, overcoming limitations of conventional proton MRS. Its simultaneous isolation of low-concentration biomarkers (PUFAs, lactate, choline) in high-fat tissues allows quantitative metabolic mapping with high spatial resolution and reduced scan times. By combining selective multiple-quantum coherence, optimized gradient schemes, and advanced coil designs, the method provides enhanced sensitivity across field strengths and nuclei, facilitating accurate detection of disease-related metabolite alterations and supporting rapid, multi-parametric clinical imaging workflows.

Description

This invention includes several modified Selective Multiple Quantum Coherence Transfer (Sel-MQC) sequences for simultaneous detection of Choline, Polyunsaturated Fatty Acids (PUFA) and Lactate, and potentially other metabolites in a spin-echo and two different multiple quantum coherence transfer pathways.

IP Status

https://patents.google.com/patent/US9915714B2

Quick Facts:
Reference Number: 01965
Technology Type: Medical Device
Technology Subtype: Diagnostic Imaging
Therapeutic Areas: Oncology
Therapeutic Indications: Ductal carcinoma (Breast cancer)
Lead Inventor: Qiuhong He
Department: Med-Radiology
All Tech Innovators: Qiuhong He
Date Submitted: 2009-03-26
Collections: Women's & Reproductive Health